Antimicrobial resistance in Neisseria gonorrhoeae in nine sentinel countries within the World Health Organization Enhanced Gonococcal Antimicrobial Surveillance Programme (EGASP), 2023: a retrospective observational study
The Lancet Regional Health - Western Pacific · 2025-08 · 61 · 101663
DOI: 10.1016/j.lanwpc.2025.101663 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Lancet Regional Health - Western Pacific, 2025-08. Verfasst von Ismael Maatouk und 25 weiteren Autor:innen. Beteiligte Einrichtung: Global HIV, Hepatitis and STI Programmes, World Health Organization (WHO), Geneva, Switzerland. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Global Fund to Fight AIDS, Tuberculosis and Malaria, World Health Organization.
Abstract (Originalsprache)
Background
The global spread of antimicrobial resistance (AMR) in Neisseria gonorrhoeae threatens empiric single-dose gonorrhoea treatment. Enhanced global AMR surveillance is imperative. We report i) gonococcal antimicrobial susceptibility and resistance data from 2023 in the World Health Organization Enhanced Gonococcal Antimicrobial Surveillance Programme (WHO EGASP) in the WHO Western Pacific Region (Cambodia, the Philippines, Viet Nam), Southeast Asian Region (Indonesia, Thailand), and African Region (Malawi, South Africa, Uganda, Zimbabwe), and ii) metadata of the gonorrhoea patients.
Methods
In 2023, WHO EGASP included men with urethral discharge (n = 3498) and gonococcal isolates (n = 2491). Minimum inhibitory concentrations (MICs, mg/L) values were determined for ceftriaxone, cefixime, azithromycin, gentamicin, and ciprofloxacin using Etest (bioMérieux). Breakpoints from the European Committee on Antimicrobial Susceptibility Testing (EUCAST) were applied. Clinical and epidemiological variables associated with AMR isolates were assessed using univariable and multivariable logistic regression analyses of odds ratios.
Findings
Overall, 3.8% (95% confidence interval (95% CI) 3.1-4.6%; 95/2487), 8.9% (95% CI 7.9-10.1%; 222/2484), 3.6% (95% CI 2.9-4.4%; 89/2487), and 95.3% (95% CI 93.2-97.5%; 1801/1890) of isolates were resistant to ceftriaxone, cefixime, azithromycin, and ciprofloxacin, respectively. All the ceftriaxone-resistant isolates were from Cambodia (15.3% (95% CI 11.5-20.1%), 42/274) and Viet Nam (20.4% (95% CI 15.9-25.7%), 53/260). In univariable analysis, ceftriaxone resistance was associated with travelling within the country during previous 30 days (OR 4.66, 95% CI 3.06-7.16; p < 0.001), and this association remained in multivariable analysis (aOR 4.12, 95% CI 2.65-6.65; p < 0.001).
Interpretation
Resistance to ceftriaxone, cefixime, and azithromycin is a major global concern, and expanded and improved resistance surveillance is essential. The WHO EGASP has been substantially expanded in the recent years. Additionally, resistance breakpoints have been harmonised and test-of-cure, whole-genome sequencing, and extragenital sampling implemented, where feasible. Novel antimicrobials for gonorrhoea treatment are critical; zoliflodacin and gepotidacin are promising. Funding: WHO, Global Fund.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Global HIV, Hepatitis and STI Programmes, World Health Organization (WHO), Geneva, Switzerland.
- Bangrak STIs Center, Division of AIDS and STIs, Department of Disease Control, Ministry of Public Health, Bangkok, Thailand.
- National Center for HIV/AIDS, Dermatology and Sexually Transmitted Diseases, Phnom Penh, Cambodia.
- University of North Carolina (UNC) Project Malawi, Lilongwe, Malawi.
- Department of Health, Research Institute for Tropical Medicine, Manila, the Philippines.
- Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda.
Förderung
- Global Fund to Fight AIDS, Tuberculosis and Malaria
- World Health Organization
Zitieren
APA
Maatouk, I., Vumbugwa, P., Cherdtrakulkiat, T., Heng, L. S., Hoffman, I., Palaypayon, N., Kakooza, F., Kittiyaowamarn, R., Kyambadde, P., Lahra, M. M., Lan, P. T., Maseko, V., Matoga, M., Machiha, A., Müller, E., Nguyen, T. T. P., Doanh, L. H., Ouk, V., Setiawaty, V., …, & WHO EGASP Study Group (2025). Antimicrobial resistance in Neisseria gonorrhoeae in nine sentinel countries within the World Health Organization Enhanced Gonococcal Antimicrobial Surveillance Programme (EGASP), 2023: a retrospective observational study. The Lancet Regional Health - Western Pacific, 61, 101663. https://doi.org/10.1016/j.lanwpc.2025.101663
Vancouver
Maatouk I, Vumbugwa P, Cherdtrakulkiat T, Heng LS, Hoffman I, Palaypayon N, et al. Antimicrobial resistance in Neisseria gonorrhoeae in nine sentinel countries within the World Health Organization Enhanced Gonococcal Antimicrobial Surveillance Programme (EGASP), 2023: a retrospective observational study. The Lancet Regional Health - Western Pacific. 2025;61:101663. doi:10.1016/j.lanwpc.2025.101663
BibTeX
@article{Maatouk2025,
author = {Maatouk, Ismael and Vumbugwa, Phiona and Cherdtrakulkiat, Thitima and Heng, Lon Say and Hoffman, Irving and Palaypayon, Noel and Kakooza, Francis and Kittiyaowamarn, Rossaphorn and Kyambadde, Peter and Lahra, Monica M and Lan, Pham Thi and Maseko, Venessa and Matoga, Mitch and Machiha, Anna and Müller, Etienne and Nguyen, Thuy Thi Phan and Doanh, Le Huu and Ouk, Vichea and Setiawaty, Vivi and Sia, Sonia B and Hartono, Teguh S and Virak, Mot and Thuy Van, Nguyen Thi and Unemo, Magnus and Wi, Teodora and WHO EGASP Study Group, WHO EGASP Study Group},
title = {Antimicrobial resistance in Neisseria gonorrhoeae in nine sentinel countries within the World Health Organization Enhanced Gonococcal Antimicrobial Surveillance Programme (EGASP), 2023: a retrospective observational study},
journal = {The Lancet Regional Health - Western Pacific},
year = {2025},
volume = {61},
pages = {101663},
doi = {10.1016/j.lanwpc.2025.101663}
}
EUVIMED